Literature DB >> 19431211

Polymorphisms in tissue inhibitors of metalloproteinases-2 and -3 and breast cancer susceptibility and survival.

Neeraja B Peterson1, Alicia Beeghly-Fadiel, Yu-Tang Gao, Jirong Long, Qiuyin Cai, Xiao-ou Shu, Wei Zheng.   

Abstract

Tissue inhibitors of metalloproteinases (TIMPs) are endogenous inhibitors of matrix metalloproteinases which are involved in normal cellular processes and also in cancer development and progression. The purpose of this study was to evaluate polymorphisms in the TIMP-2 and TIMP-3 genes for their associations with breast cancer susceptibility and survival. Using data from the Shanghai Breast Cancer Study, 19 SNPs for each gene were evaluated for associations with breast cancer risk among 1,062 cases and 1,069 controls; associations with disease-free and overall survival were evaluated among the cases. For TIMP-2, women with the rs7501477 TT genotype were 3 times more likely to be breast cancer cases than women with the CC genotype (OR: 2.9, 95% CI: 1.2-7.0). For TIMP-3, women with the rs9609643 AA genotype were 60% less likely to be breast cancer cases than women with the GG genotype (OR: 0.4, 95% CI: 0.2-1.0), whereas women with the rs8136803 TT genotype were 5 times more likely to be cases than women with the GG genotype (OR: 5.1, 95% CI: 1.1-24.3). Further, breast cancer cases with rs8136803 TT were almost 4 times more likely to have decreased disease-free survival (HR: 3.9, 95% CI: 1.4-10.6) and had a trend toward decreased overall survival (HR: 1.9, 95% CI: 0.6-6.1). An important study limitation was that these 3 SNPs (rs7501477, rs9609643, rs8136803) had low minor allele frequencies which resulted in small numbers of homozygote individuals. Genetic variation in the TIMP-2 and TIMP-3 genes may contribute to individual differences in breast cancer susceptibility and survival.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19431211      PMCID: PMC2745995          DOI: 10.1002/ijc.24405

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  38 in total

1.  Tissue inhibitor of metalloproteinase-1 alters the tumorigenicity of Burkitt's lymphoma via divergent effects on tumor growth and angiogenesis.

Authors:  L Guedez; A J McMarlin; D W Kingma; T A Bennett; M Stetler-Stevenson; W G Stetler-Stevenson
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

Review 2.  Matrix metalloproteinases in tumor invasion and metastasis.

Authors:  I Stamenkovic
Journal:  Semin Cancer Biol       Date:  2000-12       Impact factor: 15.707

Review 3.  Matrix metalloproteinases: they're not just for matrix anymore!

Authors:  L J McCawley; L M Matrisian
Journal:  Curr Opin Cell Biol       Date:  2001-10       Impact factor: 8.382

Review 4.  New functions for the matrix metalloproteinases in cancer progression.

Authors:  Mikala Egeblad; Zena Werb
Journal:  Nat Rev Cancer       Date:  2002-03       Impact factor: 60.716

Review 5.  Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis.

Authors:  S Curran; G I Murray
Journal:  Eur J Cancer       Date:  2000-08       Impact factor: 9.162

6.  Tissue inhibitor of metalloproteinase-2 G-418C polymorphism is associated with an increased risk of gastric cancer in a Chinese population.

Authors:  L Yang; H-J Gu; H-J Zhu; Q-M Sun; R-H Cong; B Zhou; N-P Tang; B Wang
Journal:  Eur J Surg Oncol       Date:  2007-10-22       Impact factor: 4.424

7.  Matrix-metalloproteinases 1, 2, and 3 and their tissue inhibitors 1 and 2 in benign and malignant breast lesions: an in situ hybridization study.

Authors:  O Brummer; S Athar; L Riethdorf; T Löning; H Herbst
Journal:  Virchows Arch       Date:  1999-12       Impact factor: 4.064

Review 8.  Complex roles of tissue inhibitors of metalloproteinases in cancer.

Authors:  Yangfu Jiang; Itzhak D Goldberg; Y Eric Shi
Journal:  Oncogene       Date:  2002-03-28       Impact factor: 9.867

9.  Association of menstrual and reproductive factors with breast cancer risk: results from the Shanghai Breast Cancer Study.

Authors:  Y T Gao; X O Shu; Q Dai; J D Potter; L A Brinton; W Wen; T A Sellers; L H Kushi; Z Ruan; R M Bostick; F Jin; W Zheng
Journal:  Int J Cancer       Date:  2000-07-15       Impact factor: 7.396

10.  Stimulation of mammary tumorigenesis by systemic tissue inhibitor of matrix metalloproteinase 4 gene delivery.

Authors:  Y Jiang; M Wang; M Y Celiker; Y E Liu; Q X Sang; I D Goldberg; Y E Shi
Journal:  Cancer Res       Date:  2001-03-15       Impact factor: 12.701

View more
  15 in total

1.  Contribution of TIMP3 polymorphisms to the development of preeclampsia in Han Chinese women.

Authors:  Changlong Guo; Xiaofang Cao; Qidi Wang; Guangyu Wang; Lisha An; Meng Du; Yue Qiu; Ying Yang; Hui Li; Yuting Wang; Shuo Wang; Xingyu Wang; Xu Ma
Journal:  J Assist Reprod Genet       Date:  2015-08-25       Impact factor: 3.412

2.  TIMP-3 -1296 T>C and TIMP-4 -55 T>C gene polymorphisms play a role in the susceptibility of hepatocellular carcinoma among women.

Authors:  Hsiu-Ting Tsai; Ming-Ju Hsieh; Hui-Ling Chiou; Hsiang-Lin Lee; Min-Chieh Hsin; Yi-Sheng Liou; Chen-Chieh Yang; Shun-Fa Yang; Wu-Hsien Kuo
Journal:  Tumour Biol       Date:  2014-06-07

3.  Association of the polymorphisms of MMP-9 and TIMP-3 genes with thoracic aortic dissection in Chinese Han population.

Authors:  Xiao-long Wang; Ou Liu; Yan-wen Qin; Hong-jia Zhang; Yi Lv
Journal:  Acta Pharmacol Sin       Date:  2014-02-03       Impact factor: 6.150

4.  Genetic polymorphisms in telomere pathway genes, telomere length, and breast cancer survival.

Authors:  Jing Shen; Marilie D Gammon; Mary Beth Terry; Patrick T Bradshaw; Qiao Wang; Susan L Teitelbaum; Alfred I Neugut; Regina M Santella
Journal:  Breast Cancer Res Treat       Date:  2012-04-12       Impact factor: 4.872

5.  Effect of tissue inhibitor of metalloproteinases-3 genetics polymorphism on clinicopathological characteristics of uterine cervical cancer patients in Taiwan.

Authors:  Jui-Fu Chung; Chia-Lin Chen; Yasser Nassef; Bei-Hao Shiu; Chun-Hao Wang; Fu-Hsuan Kuo; Yi-Hsuan Hsiao; Shun-Fa Yang; Po-Hui Wang
Journal:  Int J Med Sci       Date:  2022-05-29       Impact factor: 3.642

6.  Gene-gene interactions between TGF-β/Smad3 signalling pathway polymorphisms affect susceptibility to knee osteoarthritis.

Authors:  Sui-Lung Su; Hsin-Yi Yang; Herng-Sheng Lee; Guo-Shu Huang; Chian-Her Lee; Wan-Shan Liu; Chih-Chien Wang; Yi-Jen Peng; Ching-Huang Lai; Ching-Yang Chen; Chin Lin; Yu-Ting Pan; Donald M Salter; Hsiang-Cheng Chen
Journal:  BMJ Open       Date:  2015-06-11       Impact factor: 2.692

7.  Common germline polymorphisms associated with breast cancer-specific survival.

Authors:  Ailith Pirie; Qi Guo; Peter Kraft; Sander Canisius; Diana M Eccles; Nazneen Rahman; Heli Nevanlinna; Constance Chen; Sofia Khan; Jonathan Tyrer; Manjeet K Bolla; Qin Wang; Joe Dennis; Kyriaki Michailidou; Michael Lush; Alison M Dunning; Mitul Shah; Kamila Czene; Hatef Darabi; Mikael Eriksson; Dieter Lambrechts; Caroline Weltens; Karin Leunen; Chantal van Ongeval; Børge G Nordestgaard; Sune F Nielsen; Henrik Flyger; Anja Rudolph; Petra Seibold; Dieter Flesch-Janys; Carl Blomqvist; Kristiina Aittomäki; Rainer Fagerholm; Taru A Muranen; Janet E Olsen; Emily Hallberg; Celine Vachon; Julia A Knight; Gord Glendon; Anna Marie Mulligan; Annegien Broeks; Sten Cornelissen; Christopher A Haiman; Brian E Henderson; Frederick Schumacher; Loic Le Marchand; John L Hopper; Helen Tsimiklis; Carmel Apicella; Melissa C Southey; Simon S Cross; Malcolm Wr Reed; Graham G Giles; Roger L Milne; Catriona McLean; Robert Winqvist; Katri Pylkäs; Arja Jukkola-Vuorinen; Mervi Grip; Maartje J Hooning; Antoinette Hollestelle; John Wm Martens; Ans Mw van den Ouweland; Federick Marme; Andreas Schneeweiss; Rongxi Yang; Barbara Burwinkel; Jonine Figueroa; Stephen J Chanock; Jolanta Lissowska; Elinor J Sawyer; Ian Tomlinson; Michael J Kerin; Nicola Miller; Hermann Brenner; Katja Butterbach; Bernd Holleczek; Vesa Kataja; Veli-Matti Kosma; Jaana M Hartikainen; Jingmei Li; Judith S Brand; Keith Humphreys; Peter Devilee; Robert Aem Tollenaar; Caroline Seynaeve; Paolo Radice; Paolo Peterlongo; Siranoush Manoukian; Filomena Ficarazzi; Matthias W Beckmann; Alexander Hein; Arif B Ekici; Rosemary Balleine; Kelly-Anne Phillips; Javier Benitez; M Pilar Zamora; Jose Ignacio Arias Perez; Primitiva Menéndez; Anna Jakubowska; Jan Lubinski; Jacek Gronwald; Katarzyna Durda; Ute Hamann; Maria Kabisch; Hans Ulrich Ulmer; Thomas Rüdiger; Sara Margolin; Vessela Kristensen; Siljie Nord; D Gareth Evans; Jean Abraham; Helena Earl; Christopher J Poole; Louise Hiller; Janet A Dunn; Sarah Bowden; Rose Yang; Daniele Campa; W Ryan Diver; Susan M Gapstur; Mia M Gaudet; Susan Hankinson; Robert N Hoover; Anika Hüsing; Rudolf Kaaks; Mitchell J Machiela; Walter Willett; Myrto Barrdahl; Federico Canzian; Suet-Feung Chin; Carlos Caldas; David J Hunter; Sara Lindstrom; Montserrat Garcia-Closas; Fergus J Couch; Georgia Chenevix-Trench; Arto Mannermaa; Irene L Andrulis; Per Hall; Jenny Chang-Claude; Douglas F Easton; Stig E Bojesen; Angela Cox; Peter A Fasching; Paul Dp Pharoah; Marjanka K Schmidt
Journal:  Breast Cancer Res       Date:  2015-04-22       Impact factor: 6.466

8.  Association of SNPs in the TIMP-2 gene and large artery atherosclerotic stroke in southern Chinese Han population.

Authors:  Tie Guo; Haizhen Hao; Lv Zhou; Feng Zhou; Dan Yu
Journal:  Oncotarget       Date:  2017-12-18

9.  Genetic polymorphisms at TIMP3 are associated with survival of adenocarcinoma of the gastroesophageal junction.

Authors:  Morteza Bashash; Amil Shah; Greg Hislop; Martin Treml; Karla Bretherick; Rozmin Janoo-Gilani; Stephen Leach; Nhu Le; Chris Bajdik; Angela Brooks-Wilson
Journal:  PLoS One       Date:  2013-03-19       Impact factor: 3.240

10.  Polymorphisms and Plasma Levels of Tissue Inhibitor of Metalloproteinase-3: Impact on Genetic Susceptibility and Clinical Outcome of Oral Cancer.

Authors:  Chun-Wen Su; Yi-Wen Huang; Mu-Kuan Chen; Shih-Chi Su; Shun-Fa Yang; Chiao-Wen Lin
Journal:  Medicine (Baltimore)       Date:  2015-11       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.